Acrivon Therapeutics, Inc. ACRV
1.43 USD -0.03 (-2.05%)
Regular-session close
1.50 +0.07 +4.76%
After hours · Nov 17, 5:45 PM ET
1.40 Day range 1.56
1.27 52-week range 3.56
- YTD
- -40.66%
- 1 year
- -39.92%
News
benzinga.com Citizens Reiterates Market Outperform on Acrivon Therapeutics, Maintains $13 Price Target Citizens analyst Silvan Turkcan reiterates Acrivon Therapeutics (NASDAQ:ACRV) with a Market Outperform and maintains $13 price target.
benzinga.com Acrivon Therapeutics Q3 EPS $(0.42) Beats $(0.46) Estimate Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.42) per share which beat the analyst consensus estimate of $(0.46) by 8.7 percent. This is a 10.64 percent increase over losses of…
globenewswire.com Acrivon Reports Third Quarter 2026 Financial Results and Business Highlights Immunology and inflammation (I&I) established as a second strategic pillar for company which is particularly well-suited for its AP3 precision medicine approach
seekingalpha.com Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcript Acrivon Therapeutics, Inc. (ACRV) Discusses ACR-525 Acquisition and PKC Inhibitor Preclinical Program Transcriptbenzinga.com Acrivon Therapeutics Acquires Janus Kinase 1 Inhibitor ACR-525 From Aqilion AB; Terms Undisclosed Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
globenewswire.com Acrivon Expands into Immunology and Inflammation with Acquisition of Phase 2-Ready Differentiated, Oral JAK1 Inhibitor ACR-525, and PKCθ Inhibitor Preclinical Program from Aqilion AB Asset acquisition establishes immunology and inflammation (I&I) as a strategic pillar alongside oncology, extending the company into autoimmune disease
globenewswire.com Acrivon to Present Late-Breaking Oral Plenary Presentation and Posters at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics WATERTOWN, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…benzinga.com Acrivon Therapeutics To Present Dose Escalation Data From Its Current Phase 1/2 Trial Of ACR-2316 At 38th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (Nasdaq: ACRV), a clinical-stage biotechnology company discovering and developing precision medicines utilizing its proprietary…
globenewswire.com Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium Timothy A. Yap, MBBS, Ph.D., FRCP, of The University of Texas MD Anderson Cancer Center to present results from the dose escalation phase of the ACR-2316 Phase 1/2 trial on November 20, 2026 Durable…benzinga.com Acrivon Therapeutics Advances ACR-7280, Showing Complete Tumor Regression In AML Models, With IND Filing Targeted For H1 2027 ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft modelsPrioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent…
globenewswire.com Acrivon Advances ACR-7280, an Optimized, AP3-Enabled, Potential First-in-Class, Oral CDK11 Inhibitor Toward IND Filing in First Half of 2027 ACR-7280 demonstrated complete tumor regression in aggressive AML xenograft models Prioritized among multiple AP3-discovered, highly selective CDK11 inhibitor candidates based on potent single agent…
zacks.com What Makes Acrivon Therapeutics, Inc. (ACRV) a New Buy Stock Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com Acrivon Therapeutics, Inc. (ACRV) Just Flashed Golden Cross Signal: Do You Buy? Acrivon Therapeutics, Inc. (ACRV) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ACRV's 50-day simple moving average…
globenewswire.com Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference WATERTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…
globenewswire.com Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer Experienced biotechnology executive brings an extensive track record in business development, strategic transactions, licensing and corporate strategy Experienced biotechnology executive brings an…
zacks.com Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.
globenewswire.com Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts ACR-368 Phase 2b prespecified interim analysis and data from all-comer serous endometrial cancer (EC) treatment arms on track for second half of 2026
globenewswire.com Acrivon Advances ACR-2316, a Potential First-in-Class WEE1/PKMYT1 Inhibitor, into Randomized Dose Expansion in its Ongoing Phase 1/2 Study Favorable, differentiated safety profile and durable single-agent clinical activity, including in heavily pretreated subjects with lung cancer remaining on treatment for over a year Oral weekly…
globenewswire.com Acrivon to Highlight the Power of its AP3 Platform for Streamlined, Pathway-Based Drug Discovery and Development with Oral and Poster Presentations at AACR D3 Conference Presentations feature mechanistic data on ACR-2316, a potential first-in-class, clinical WEE1/PKMYT1 inhibitor, rationally designed with AP3 for potent single agent activity and superior therapeutic…
seekingalpha.com Acrivon Therapeutics: Priced For Failure, Built For Precision Acrivon Therapeutics (ACRV) trades below cash value, with the market deeply discounting its platform and pipeline despite promising early data. ACRV's AP3 platform enables precision patient-matching…
globenewswire.com Acrivon Therapeutics to Present at TD Cowen's 7th Annual Oncology Innovation Summit WATERTOWN, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…
globenewswire.com Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., May 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…
globenewswire.com Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer (biopsy-independent) serous endometrial cancer arms…
globenewswire.com Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition
globenewswire.com Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) WATERTOWN, Mass., April 15, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing…
